re: trademark secured Another step is done. Now they just need...

re: trademark secured Another step is done. Now they just need to replicate the spectacular success they saw with the Renal Cell patient in the phase 1 trial. When you look at what is currently available you can see just how good that response against RCC was.
This is the other new RCC drug on the market.

"Nexavar(R) is a drug to suppress cancer growth by stopping the signalling cascade for proliferation of tumor cells and inhibiting angiogenesis which generates vessels to the newly proliferated tumor cells. In ASCO 2005, a prolongation of progression-free survival period was presented using the data of global Phase III which more than 900 RCC patients joined. According to that, time to progression or death on placebo group was 84 days, whereas it was 167 days (p<0.000001) on the group treated by Nexavar(R). In ASCO 2006 held in this June, an interim data on the overall survival was presented to show positive results of Nexavar(R)."
I guess that is why Stutent TTP of 11 month. looked so good. If Solbec can repeat the previous phase 1 result on a larger scale in Phase 2 it would be considerably better than the current approved treatments. Just my opinion, do your own DD
http://www.japancorp.net/Article.Asp?Art_ID=12803